IGM Biosciences Stock Forecast, Price & News

+4.30 (+6.10 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume254,646 shs
Average Volume106,462 shs
Market Capitalization$2.40 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IGMS News and Ratings via Email

Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IGM Biosciences logo

About IGM Biosciences

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.20 out of 5 stars

Medical Sector

352nd out of 1,350 stocks

Pharmaceutical Preparations Industry

171st out of 664 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

IGM Biosciences (NASDAQ:IGMS) Frequently Asked Questions

Is IGM Biosciences a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IGM Biosciences stock.
View analyst ratings for IGM Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than IGM Biosciences?

Wall Street analysts have given IGM Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IGM Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting IGM Biosciences?

IGM Biosciences saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 3,330,000 shares, an increase of 12.9% from the July 29th total of 2,950,000 shares. Based on an average daily volume of 144,700 shares, the short-interest ratio is currently 23.0 days. Currently, 23.1% of the company's shares are sold short.
View IGM Biosciences' Short Interest

When is IGM Biosciences' next earnings date?

IGM Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for IGM Biosciences

How were IGM Biosciences' earnings last quarter?

IGM Biosciences, Inc. (NASDAQ:IGMS) released its quarterly earnings data on Sunday, August, 8th. The company reported ($1.16) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($1.16).
View IGM Biosciences' earnings history

How has IGM Biosciences' stock been impacted by Coronavirus (COVID-19)?

IGM Biosciences' stock was trading at $52.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IGMS shares have increased by 43.0% and is now trading at $74.82.
View which stocks have been most impacted by COVID-19

What price target have analysts set for IGMS?

5 Wall Street analysts have issued 1-year price objectives for IGM Biosciences' shares. Their forecasts range from $82.00 to $121.00. On average, they expect IGM Biosciences' stock price to reach $104.17 in the next year. This suggests a possible upside of 39.2% from the stock's current price.
View analysts' price targets for IGM Biosciences
or view top-rated stocks among Wall Street analysts.

Who are IGM Biosciences' key executives?

IGM Biosciences' management team includes the following people:
  • Mr. Fred M. Schwarzer, CEO, Pres & Director (Age 68, Pay $847.52k)
  • Dr. Bruce A. Keyt, Chief Scientific Officer (Age 68, Pay $636.33k) (LinkedIn Profile)
  • Dr. Shinyu Chen M.D., Ph.D., Chief Medical Officer (Age 52, Pay $675.25k)
  • Mr. Misbah Tahir, Chief Financial Officer (Age 46)
  • Mr. Paul C. Graffagnino, VP of Legal Affairs
  • Ms. Suzette Tauber, Chief HR Officer (Age 57)
  • Dr. Lisa L. Decker Ph.D., Chief Bus. Officer (Age 52)
  • Mr. George A. Gauthier, Chief Commercial Officer (Age 49)
  • Mr. Marvin S. Peterson Ph.D., Sr. VP, Process Sciences & Manufacturing
  • Mr. Angus Sinclair, VP of Immuno-Oncology

Who are some of IGM Biosciences' key competitors?

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).

When did IGM Biosciences IPO?

(IGMS) raised $125 million in an initial public offering on Wednesday, September 18th 2019. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What is IGM Biosciences' stock symbol?

IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS."

Who are IGM Biosciences' major shareholders?

IGM Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.19%), Woodline Partners LP (2.32%), BlackRock Inc. (1.98%), State Street Corp (1.83%), Goldman Sachs Group Inc. (1.32%) and Vanguard Group Inc. (1.28%). Company insiders that own IGM Biosciences stock include Bros Advisors Lp Baker, Bruce Keyt, Daniel Shinyu Chen, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Redmile Group, Llc and Topsoe Holding A/S Haldor.
View institutional ownership trends for IGM Biosciences

Which major investors are selling IGM Biosciences stock?

IGMS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Ikarian Capital LLC, BlackRock Inc., State Street Corp, FMR LLC, Susquehanna International Group LLP, Citadel Advisors LLC, and Rafferty Asset Management LLC. Company insiders that have sold IGM Biosciences company stock in the last year include Bruce Keyt, Daniel Shinyu Chen, and Julie Hambleton.
View insider buying and selling activity for IGM Biosciences
or view top insider-selling stocks.

Which major investors are buying IGM Biosciences stock?

IGMS stock was purchased by a variety of institutional investors in the last quarter, including Woodline Partners LP, Price T Rowe Associates Inc. MD, UBS Asset Management Americas Inc., Bruce & Co. Inc., Altium Capital Management LP, Eagle Bay Advisors LLC, Russell Investments Group Ltd., and Ensign Peak Advisors Inc. Company insiders that have bought IGM Biosciences stock in the last two years include Bros Advisors Lp Baker, Jakob Haldor Topsoe, M Kathleen Behrens, Redmile Group, Llc, and Topsoe Holding A/S Haldor.
View insider buying and selling activity for IGM Biosciences
or or view top insider-buying stocks.

How do I buy shares of IGM Biosciences?

Shares of IGMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IGM Biosciences' stock price today?

One share of IGMS stock can currently be purchased for approximately $74.82.

How much money does IGM Biosciences make?

IGM Biosciences has a market capitalization of $2.40 billion. The company earns $-81,360,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.

How many employees does IGM Biosciences have?

IGM Biosciences employs 107 workers across the globe.

What is IGM Biosciences' official website?

The official website for IGM Biosciences is

Where are IGM Biosciences' headquarters?

IGM Biosciences is headquartered at 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043.

How can I contact IGM Biosciences?

IGM Biosciences' mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-965-7873.

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.